Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Dey

Showing results (151-160 of 202) with videos related to

Pageof 21
Sort By:
British Journal of Haematology|January 26, 2005
Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantationBimalangshu R Dey, Steven McAfee, Christine Colby, et al.
The Oncologist|July 17, 2021
Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation RecipientsAnnabelle J Anandappa, Gabriela S Hobbs, Bimalangshu R Dey, et al.
Nature Genetics|September 1, 1992
Human cystic fibrosis transmembrane conductance regulator directed to respiratory epithelial cells of transgenic miceJ A Whitsett, C R Dey, B R Stripp, et al.
Bone Marrow Transplantation|July 1, 2008
Clinical outcomes of late rather than early full-donor chimerism in patients with advanced lymphomas receiving nonmyeloablative allogeneic hematopoietic SCTD T Ting, T R Spitzer, A Chaudhary, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2007
Phase I trial of parathyroid hormone to facilitate stem cell mobilizationKaren K Ballen, Elizabeth J Shpall, David Avigan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2014
Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantationAlbert C Yeh, Andrew M Brunner, Thomas R Spitzer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2013
Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experienceAazim K Omer, Panayiotis D Ziakas, Theodora Anagnostou, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experienceMatthew Ulrickson, Julie Aldridge, Haesook T Kim, et al.
Bone Marrow Transplantation|October 9, 2012
Expression of α4β7 integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHDY-B Chen, S McDonough, H Chen, et al.
Experimental Hematology|June 26, 2007
Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabineJuanita Shaffer, Jean Villard, Terry K Means, et al.
Pageof 21

Showing results (151-160 of 202) with videos related to

Sort By:
Pageof 21
British Journal of Haematology|January 26, 2005
Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantationBimalangshu R Dey, Steven McAfee, Christine Colby, et al.
The Oncologist|July 17, 2021
Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation RecipientsAnnabelle J Anandappa, Gabriela S Hobbs, Bimalangshu R Dey, et al.
Nature Genetics|September 1, 1992
Human cystic fibrosis transmembrane conductance regulator directed to respiratory epithelial cells of transgenic miceJ A Whitsett, C R Dey, B R Stripp, et al.
Bone Marrow Transplantation|July 1, 2008
Clinical outcomes of late rather than early full-donor chimerism in patients with advanced lymphomas receiving nonmyeloablative allogeneic hematopoietic SCTD T Ting, T R Spitzer, A Chaudhary, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2007
Phase I trial of parathyroid hormone to facilitate stem cell mobilizationKaren K Ballen, Elizabeth J Shpall, David Avigan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2014
Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantationAlbert C Yeh, Andrew M Brunner, Thomas R Spitzer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2013
Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experienceAazim K Omer, Panayiotis D Ziakas, Theodora Anagnostou, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experienceMatthew Ulrickson, Julie Aldridge, Haesook T Kim, et al.
Bone Marrow Transplantation|October 9, 2012
Expression of α4β7 integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHDY-B Chen, S McDonough, H Chen, et al.
Experimental Hematology|June 26, 2007
Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabineJuanita Shaffer, Jean Villard, Terry K Means, et al.
Pageof 21